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A B S T R A C T
Purpose
Second malignant neoplasms (SMNs) after diagnosis of childhood acute lymphoblastic leukemia
(ALL) are rare events.
Patients and Methods
We analyzed data on risk factors and outcomes of 642 children with SMNs occurring after
treatment for ALL from 18 collaborative study groups between 1980 and 2007.
Results
Acute myeloid leukemia (AML; n  186), myelodysplastic syndrome (MDS; n  69), and
nonmeningioma brain tumor (n  116) were the most common types of SMNs and had the
poorest outcome (5-year survival rate, 18.1%  2.9%, 31.1%  6.2%, and 18.3%  3.8%,
respectively). Five-year survival estimates for AML were 11.2%  2.9% for 125 patients
diagnosed before 2000 and 34.1% 6.3% for 61 patients diagnosed after 2000 (P .001); 5-year
survival estimates for MDS were 17.1%  6.4% (n  36) and 48.2%  10.6% (n  33; P  .005).
Allogeneic stem-cell transplantation failed to improve outcome of secondary myeloid malignancies
after adjusting for waiting time to transplantation. Five-year survival rates were above 90% for
patients with meningioma, Hodgkin lymphoma, thyroid carcinoma, basal cell carcinoma, and
parotid gland tumor, and 68.5%  6.4% for those with non-Hodgkin lymphoma. Eighty-nine
percent of patients with brain tumors had received cranial irradiation. Solid tumors were
associated with cyclophosphamide exposure, and myeloid malignancy was associated with
topoisomerase II inhibitors and starting doses of methotrexate of at least 25 mg/m2 per week and
mercaptopurine of at least 75 mg/m2 per day. Myeloid malignancies with monosomy 7/5q were
associated with high hyperdiploid ALL karyotypes, whereas 11q23/MLL-rearranged AML or MDS
was associated with ALL harboring translocations of t(9;22), t(4;11), t(1;19), and t(12;21) (P  .03).
Conclusion
SMNs, except for brain tumors, AML, and MDS, have outcomes similar to their
primary counterparts.
J Clin Oncol 31:2469-2476. © 2013 by American Society of Clinical Oncology
INTRODUCTION
Asmanyasone thirdof all deaths in childhoodacute
lymphoblastic leukemia (ALL) are caused by toxici-
ties or secondmalignantneoplasms (SMNs).1-4 Pre-
viously reported cumulative incidences of SMNs
have varied from less than 1% to 10% or more be-
cause of differences in antileukemic therapy and in
duration, accuracy, and completeness of follow-
up.1,2,5-18 Partly because of their rarity, little is known
about the etiology of SMNs or about the treatment
options that offer the best chances of cure.1
With the goal of improving overall survival in
childhood ALL and providing guidelines for treat-
ment, the international Ponte di Legno consortium
of ALL study groups has studied uncommon sub-
groups of childhood ALL.19-23 This is the largest
study of SMNs after therapy for childhood ALL
reported to date, and it presents newpotential risk
factors and provides survival rates for dis-
tinct subsets.
PATIENTS AND METHODS
Review of Patient Data
In the February 2010 issue of Leukemia, 16 coopera-
tive study groups from Europe, North America, and Asia
reported clinical outcomes, including the occurrence of
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SMNs, of 54,068 children and adolescents up to 21 years of age with newly
diagnosed ALL enrolled onto controlled clinical trials between 1980 and
2007.5-17,24-26 From these 16 groups as well as from FRALLE (French Acute
Lymphoblastic Leukaemia StudyGroup) and the childhood leukemia branch
of the European Organisation for Research and Treatment of Cancer
(EORTC), we collected data on individuals with SMNs to form a common
database with predefined variables comprising clinical and biologic data (in-
cluding cytogenetic characteristics formyeloidneoplasias) aswell as outcomes
(Appendix Table A1, online only). Furthermore, we recorded clinical and
biologic characteristics of their primary ALL as well as treatment given and
status at latest follow-up. The data available for this study were retrieved from
the groups’ central ALL databases. If patient data on drug doses were unavail-
able, the patientswere assigned the drugs anddoses listed in theALLprotocols
onto which they were enrolled. Accrual of data for patients with ALLwho did
not develop SMNswas not part of the study. The study was approved accord-
ing to regional institutional review board requirements. All data were com-
piled at Rigshospitalet (Copenhagen, Denmark), and the database was
approved by the Danish Data Protection Authorities.
Statistical Analysis
Differences in distribution of individual parameters among subsets were
analyzedbyusingnonparametric tests.27 Since accrual ofdata forpatientswith
ALL who did not develop SMNs was not part of this study, odds ratios for
SMNs in relation to specific exposures are not included. Instead, we analyzed
patterns of ALL characteristics and therapy by subsets of SMNs to determine
whether certain ALL subtypes or drug exposures were more prevalent within
specific subsets of SMNs. Survival after an SMN was defined as time from
diagnosis of the SMN to death as a result of any cause or to last follow-up. The
Kaplan-Meier method was used to estimate survival rates with SEs calculated
according to Greenwood.28 Differences in survival rates were compared with
the log-rank test.29 The Cox proportional hazardmodel was used for selected
analysis of survival after SMNs.30 Two-sidedP values below .05were regarded
as significant.
RESULTS
In all, 659 patients diagnosed with ALL between 1980 and 2007 were
registeredwithamalignantneoplasmoraCNStumoras thefirst event
after diagnosis of ALL. Seventeen SMNs reported as ALL (n  12),
acute undifferentiated leukemia (n  2), or myeloid malignancies
with monosomy 7 (n 1) or t(9;22)(q34;q11.2) (n 2) at diagnosis
of both ALL and the subsequent SMNs were excluded because the
clonal relationship to the original leukemia could not be confidently
verified, leaving a total of 642 study patients.
Table 1 reports clinical informationon the642SMNsby subtype.
The interval between diagnosis of ALL and occurrence of SMNs was
significantly associated with the subtype of SMN, being shortest for
hematologicmalignancies and longest for carcinomas andmeningio-
mas (P .001; Fig 1 and Table 1). Thus, among the 48 SMNs diag-
nosed more than 15 years from the diagnosis of ALL, 35% were
meningiomas (n  15) or other CNS tumors (n  2); 31% were
non–skin carcinomas (n  15), including six thyroid cancers; 15%
weremelanomas (n 4) or other skin cancers (n 3); and 17%were
hematologic malignancies (n  5); sarcomas (n  2); or testicular
cancer (n 2). Eight patients with cancer-predisposing diseases are
described in Appendix Table A2 (online only).
Patterns of SMNs by ALL-Presenting Features
Althoughdistributionof sex, age, andWBCcount at diagnosis of
ALL varied significantly among the major categories of SMNs for the
entire cohort (Table 1), this was not the case for the subset of 201
patients who were not irradiated and did not undergo hematopoietic
stem-cell transplantation during first-line ALL treatment (P .45 for
all analyses; Appendix Table A3, online only).
Immunophenotype
Ofthe186patientswithAMLand69patientswithmyelodysplas-
tic syndrome (MDS), the ALL lineage (B-cell precursor or T-cell
lineage) was available for 217 patients. When analyzing only the 192
patientswhodidnot receive irradiation anddidnot receive transplan-
tation but who did have ALL immunophenotype available, the prev-
alenceofT-cellALLdidnotdiffer significantlyamongthecategoriesof
hematologic malignancies, CNS tumors, carcinomas, and other tu-
mors (7.8%,10.0%, and16.7%, respectively;P .38), but 26.6%of all
patientswithAML(42of 158) and8.5%of all patientswithMDS (five
of 59) initially had T-cell ALL. Patients with AML were overall more
likely than those with other hematologic malignancies (n  136) to
have had T-cell ALL (26.6% v 13.2%; P .005) with the same trend
(10.0% v 5.6%; P .33) in the subsets of patients who did not receive
irradiation and did not receive transplantation. The interval between
diagnosis ofALLandSMNwas significantly shorter for the 11patients
whodidnot receive irradiationanddidnot receive transplantationbut
who had T-cell ALL than for the 130 patients with B-cell precursor
ALLwho had developed hematologicmalignancies (median, 1.6 v 3.0
years;P .001). Finally, 91%(10of 11) of the patientswhodeveloped
Langerhans cell histiocytosis had T-cell ALL compared with 20.4%
among the other SMNs (P .001).
Karyotype and Therapy-Related Myeloid Neoplasias
The time to develop AML was shorter than the time to develop
MDS (median, 2.7 v 3.3 years;P .01), reflecting a higher proportion
of 11q23/MLL rearrangements with short latency (median, 2.5 years)
in patients with AML (58% v 5% of patients with MDS with an
aberrant karyotype;P .001). By contrast, treatment-relatedmyeloid
neoplasia (t-MN; ie, AMLorMDS)withmonosomy 7 (median inter-
val, 3.7 years) occurred in 22% of patients with AML and in 50% of
patients withMDS with an aberrant karyotype (P .002).
Among the 44 patients with t-MN with monosomy 7, 5q, or
11q23/MLL rearrangements (one t-MN with both monosomy 7 and
11q23/MLL rearrangementswas excluded) andanavailable karyotype
for the ALL clone, the cytogenetic aberrations of their ALL and t-MN
were highly correlated. Thus, among the 25 patients who developed
11q23/MLL-rearranged t-MN, 13 had ALL with classical recurrent
translocations—t(9;22)(q34;q11.2) (n 1), t(1;19)(q23;p13.3) (n
2), t(12;21)(p13;q22) (n 8), or 11q23/MLL rearrangements (n 2
[different 11q23/MLL rearrangement in the two clones]—and six had
a high hyperdiploid ALL karyotype (modal chromosome number
above50), and sixhadother structural and/ornumeric aberrations. In
contrast, among the 19 patients who developed t-MN with 5q– or
monosomy 7, 10 had a high hyperdiploid ALL karyotype, three had
ALLcloneswithoneof theabove-listedclassical translocations, andsix
had other aberrations (P .03 by likelihood-ratio 2 test).
Patterns of SMNs by ALL Therapy
The pattern of SMNswas significantly influenced by the preced-
ingALL therapy (Table 2). The 12 patientswithCNS tumorswhohad
not received CNS irradiation were diagnosed at significantly shorter
intervals after ALL than the 97 patients with CNS tumors that oc-
curred after CNS irradiation (median, 6.6 v 9.1 years; P .01).
Schmiegelow et al
2470 © 2013 by American Society of Clinical Oncology JOURNAL OF CLINICAL ONCOLOGY
Ta
bl
e
1.
C
lin
ic
al
C
ha
ra
ct
er
is
tic
s
an
d
5-
Y
ea
r
O
ve
ra
ll
S
ur
vi
va
lo
f
64
2
P
at
ie
nt
s
W
ith
S
M
N
s
by
M
aj
or
C
at
eg
or
ie
s
an
d
S
ub
ty
pe
Ty
pe
of
S
M
N
To
ta
l
M
al
es
A
LL
Im
m
un
op
he
no
ty
pe

(n

55
5)
A
ge
at
A
LL
(y
ea
rs
)
W
B
C
at
A
LL
(
10
9
/L
)
In
te
rv
al
to
S
M
N
(y
ea
rs
)
A
ge
at
S
M
N
(y
ea
rs
)
5-
Y
ea
r
S
ur
vi
va
l
R
at
e
A
ft
er
S
M
N
(%
)
N
o.
%
N
o.
%
B
C
P
%
M
ed
ia
n
50
%
R
an
ge
M
ed
ia
n
50
%
R
an
ge
M
ed
ia
n
50
%
R
an
ge
M
ed
ia
n
50
%
R
an
ge
To
ta
l
64
2
34
6
53
.9
43
4
78
.2
5.
2
3.
2-
10
.3
11
.4
4.
7-
45
.0
4.
8
2.
6-
8.
9
12
.6
7.
8-
17
.5
40
.4

2.
1†
H
em
at
ol
og
ic
34
5
53
.7
19
8
57
.4
23
4
79
.6
5.
2
3.
2-
11
.2
9.
0
4.
2-
37
.0
2.
9
2.
0-
4.
5
9.
4
6.
5-
15
.2
35
.2

2.
7
A
cu
te
m
ye
lo
id
le
uk
em
ia
18
6
10
6
57
.0
11
6
73
.4
5.
6
3.
3-
11
.2
11
.6
4.
2-
45
.0
2.
7
1.
8-
4.
5
9.
5
6.
4-
15
.0
18
.1

2.
9
M
ye
lo
dy
sp
la
st
ic
sy
nd
ro
m
e
69
32
46
.4
54
91
.5
5.
2
3.
1-
12
.2
6.
0
3.
8-
12
.7
3.
3
2.
6-
4.
6
9.
7
6.
9-
15
.9
31
.1

6.
2
C
hr
on
ic
m
ye
lo
id
le
uk
em
ia
9
4
44
.4
7
10
0.
0
12
.5
4.
2-
15
.1
9
4.
0-
28
.5
4.
1
3.
5-
7.
2
18
.0
17
.4
-1
9.
3
62
.2

17
.8
N
on
–H
od
gk
in
ly
m
ph
om
as
56
39
69
.6
39
83
.0
4.
7
3.
0-
8.
6
11
.2
4.
3-
31
.8
2.
3
1.
5-
4.
0
7.
8
5.
5-
12
.1
68
.5

6.
4
H
od
gk
in
di
se
as
e
25
17
68
.0
18
78
.3
4.
2
3.
0-
9.
2
7.
4
5.
0-
45
.0
4.
1
2.
6-
5.
3
10
.2
6.
9-
14
.9
91
.1

6.
0
C
N
S
tu
m
or
13
8
21
.5
67
48
.6
94
78
.3
4.
2
2.
6-
8.
7
15
.7
6.
1-
59
.0
8.
6
6.
8-
11
.2
14
.7
11
.0
-1
9.
2
25
.9

4.
2
N
on
m
en
in
gi
om
a
C
N
S
tu
m
or
11
6
53
45
.7
79
77
.5
4.
4
2.
7-
8.
7
18
.7
6.
9-
82
.8
8.
1
6.
5-
9.
8
13
.9
10
.5
-1
6.
5
18
.3

3.
8
M
en
in
gi
om
a
22
14
63
.6
15
83
.3
3.
5
2.
3-
8.
5
9
5.
1-
30
.0
16
.2
12
.3
-1
8.
3
21
.7
17
.8
-2
5.
4
90
.9

8.
7
C
ar
ci
no
m
a
78
12
.1
34
43
.6
62
84
.9
5.
8
3.
3-
10
.6
12
.3
4.
0-
45
.6
10
.1
6.
7-
14
.5
17
.5
12
.4
-2
2.
2
82
.2

4.
9
N
on
th
yr
oi
d
ca
rc
in
om
a
46
19
41
.3
35
81
.4
8.
4
3.
9-
13
.0
12
.9
3.
6-
38
.5
10
.2
6.
1-
15
.0
18
.0
12
.4
-2
5.
8
67
.3

8.
2
Th
yr
oi
d
ca
rc
in
om
a
32
15
46
.9
27
90
.0
5.
0
3.
1-
6.
5
12
.1
4.
3-
58
.5
10
.1
7.
8-
13
.5
15
.5
12
.1
-1
8.
3
10
0
O
th
er
81
12
.6
47
58
.0
44
64
.7
5.
7
4.
0-
10
.4
14
.0
4.
9-
79
.9
6.
8
3.
4-
10
.0
14
.1
8.
2-
17
.9
55
.3

6.
1
S
of
t
tis
su
e
sa
rc
om
a
29
14
48
.3
14
60
.9
6.
0
4.
1-
10
.4
19
.8
7.
3-
66
.0
5.
4
3.
3-
9.
6
13
.3
8.
0-
17
.2
43
.9

9.
7
B
on
e
tu
m
or
22
13
59
.1
14
77
.8
5.
3
2.
9-
8.
1
7.
0
3.
1-
30
.9
7.
8
5.
2-
11
.4
14
.4
11
.9
-1
7.
9
61
.9

11
.6
M
el
an
om
a
11
6
54
.6
9
90
.0
10
.0
5.
7-
13
.9
10
.0
4.
7-
30
.9
10
.0
6.
3-
17
.8
19
.2
16
.7
-2
4.
3
85
.7

13
.2
G
er
m
ce
ll
tu
m
or
4
4
10
0.
0
3
10
0.
0
12
.7
8.
1-
15
.2
7.
8
2.
6-
13
.2
12
.3
8.
4-
19
.8
22
.9
20
.2
-3
1.
4
10
0
H
is
tio
cy
to
si
s
12
9
75
.0
2
16
.7
4.
2
2.
5-
5.
5
14
1.
0
40
.4
-2
48
.5
2.
3
1.
4-
3.
9
6.
9
6.
0-
8.
2
48
.6

14
.8
O
th
er
3
1
33
.3
2
10
0.
0
9.
9
4.
1-
12
.3
4.
0
2.
2-
14
8.
0
7.
6
3.
3-
9.
8
15
.5
13
.9
-1
7.
5
33
.3

27
.2
A
bb
re
vi
at
io
ns
:
A
LL
,
ac
ut
e
ly
m
ph
ob
la
st
ic
le
uk
em
ia
;
B
C
P
,
B
-c
el
lp
re
cu
rs
or
;
S
M
N
,
se
co
nd
m
al
ig
na
nt
ne
op
la
sm
.

In
al
l,
87
pa
tie
nt
s
w
er
e
ex
cl
ud
ed
be
ca
us
e
im
m
un
op
he
no
ty
pe
w
as
no
t
re
po
rt
ed
(n

75
)
or
w
as
no
t
sp
ec
ifi
ed
as
ei
th
er
B
C
P
or
T-
ce
ll
A
LL
(n

12
).
†T
en
-y
ea
r
su
rv
iv
al
ra
te
w
as
38
.7
%

2.
2%
.
SMNs After Childhood ALL
www.jco.org © 2013 by American Society of Clinical Oncology 2471
Thirty-eight (76.0%) of 50 patients with t-MNwith an aberrant
karyotype and previous exposure to epipodophyllotoxins had 11q23/
MLL rearrangements,whereasonly four (8.0%)hadmonosomy7and
none had 5q–. In contrast, among the 46 patients with t-MN (52.2%)
who had not been exposed to epipodophyllotoxins, 24 developed
monosomy7 (n 20) or 5q– (n 4) t-MN, andonly 13 (28.3%)had
11q23/MLL rearrangements (P .001).
Among patients who did not receive irradiation, 44 (79%) of 56
patientswith solid tumors hadpreviously received cyclophosphamide
comparedwith 82 (57%) of 143 patients with hematologicmalignan-
cies or CNS tumors (P .005).
Among the patients who did not receive transplantation for
whom data on maintenance therapy methotrexate (n  431) and
mercaptopurine dosage (n  422) were available, the patients who
developed t-MN received higher starting doses of methotrexate and
mercaptopurine than did patients who developed other SMNs (P
.001 for both drugs), and this was the case for both CNS patients who
received irradiation (P .001 and P .001, respectively) and those
who did not (P  .007 and P  .02, respectively). Thus, compared
with patients with other SMNs, the patients who developed t-MNs
were more likely to have received methotrexate starting doses of at
least 25mg/m2 per week (45% v 28%; P .001) andmercaptopurine
starting doses of at least 75 mg/m2 per day (52% v 29%; P .001).
Neither the distribution of the four major categories of SMNs
(P .37) nor the time interval to SMN(P .84) differed significantly
between patients with low (n  13; 10 by genotype and three by
phenotype) versus normal (n  114) thiopurine methyltransferase
activity. Among the 413 patients who did not undergo transplan-
tation but who did have data on the total duration of therapy, 65
(31.3%) of the 208 patients with t-MN and 36 (17.6%) of the 205
patients with solid tumors had received ALL therapy for 2.5 years
or longer (P .001).
Transplantation during first remission of ALL had been per-
formed in 29 (5.7%) of the 510 ALL patients with available informa-
tion.One (1.4%) of 74 patientswithCNS tumors and seven (3.6%) of
193 patients with t-MN had received transplantation compared with
nine (28.1%) of 32 patients with carcinomas and eight (15.4%) of 52
with other SMNs (P .001).
Survival After SMNs
Themedian follow-up after diagnosis of an SMNwas 4.9 years
for the 292 patients who were alive at their latest follow-up. In all,
350 patients died within 20.6 years from diagnosis of an SMN
(median, 0.75 years; 25th to 75th percentile: 0.4 to 1.4). The overall
cumulative probability of death as a result of any cause was
59.6%  2.1% at 5 years and 61.3%  2.2% at 10 years after an
SMN (Table 1 and Fig 2). The 10-year cumulative incidence of
death as a result of the second (n 236) or third (n 1) cancerwas
41.1%  2.1%; it was 5.6%  1.0% for relapsed ALL (n  31),
10.4% 1.3% for treatment-related toxicities among patients who
received a transplantation (n  39) and those who did not
(n  20), and 4.2%  0.9% for unknown causes (n  23; Fig 3).
The 10-year probability of survival was 18.9% 6.9% (n 33) for
patientswhose SMNoccurred before 1990 (n 54), 34.8% 2.8%
(n  296) for patients with SMNs diagnosed between 1990 and
1999, and 40.9%  6.3% (n  313) for patients diagnosed from
2000 onward (P .001).
Hematologic Malignancies
Survival remained consistently lower for patients with AML
compared with those who had MDS (P .001). The 5-year survival
estimate for AML was 11.2%  2.9% for 125 patients diagnosed
before 2000 and 34.1% 6.3% for 61 patients diagnosed after 2000
(P  .001). For MDS, the 5-year survival was 17.1% 6.4% for 36
patients diagnosed before 2000 and 48.2%  10.6% for 33 patients
diagnosed after 2000 (P .005). In aCox regressionmodel, adjusting
for sexandageatdiagnosisof SMNsand theuseofCNS irradiation for
ALL treatment, the improved outcome after 2000 was confirmed for
both AML (estimated hazard ratio [HR], 0.62; 95% CI, 0.42 to 0.90;
P .01) and MDS (HR, 0.30; 95% CI, 0.15 to 0.60; P .001). The
hazard of death after t-MNdecreased by approximately 10% for every
additional year of interval between ALL andAML (HR, 0.88; 95%CI,
0.80 to 0.96; P .004) with a similar trend for MDS (HR, 0.92; 95%
CI, 0.80 to 1.06; P .23).
For 185 patients with available information on transplantation
after t-MN, the 5-year survival was 30.3% 4.4% for the 119 patients
who received a transplantation and 11.4% 4.0% for the 66who did
not (P .001).However, with a landmark at themedianwaiting time
to transplantation of 4.1 months from SMN diagnosis, the 5-year
survival estimates for patients who had received a transplantation and
those who had not did not differ (26.7% 4.2% and 27.2% 7.7%,
respectively),28,31 and this was also the case for 78 patients with t-MN
diagnosed in 2000 or later (42.0% 7.6% v 46.9% 11.5%). Among
the patients with t-MN who received a transplantation, the 10-year
survival for 30 patients with 11q23/MLL rearrangements (24.7% 
8.3%) did not differ significantly from that of 26 patients withmono-
somy 7 (28.0% 9.0%).
Only two of the 25 patients with Hodgkin lymphoma died, both
of whom were diagnosed with Hodgkin lymphoma in the 1980s.
Excluding patients who received transplantation as part of their ALL
therapy, the 5-year survivalwas 70.5%7.9% for the 34patientswith
non-Hodgkin lymphomadiagnosed in the 1990s and 65.4% 10.8%
for the 22 patients diagnosed later (P .64). The 5-year survival was
76.9% 8.3% for the 27 patients who had developed mature B-cell
non-Hodgkin lymphoma.
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CNS Tumors
Although only one of 22 patients with meningioma died, the
5-year survivalwasverypoor for the remaining116patientswithbrain
tumors (18.3%  3.8%), including eight patients with low-grade
tumors (45.0% 18.8%), 76 with high-grade tumors including me-
dulloblastomas and supratentorial primitive neuroectodermal tu-
mors (6.5%3.6%), and13unspecified glial tumors (8.5%8.2%).
Overall survival after nonmeningioma brain tumor did not improve
over time, with 5-year estimates of 19.6%  5.5% before 2000 and
16.6% 5.3% afterward (P .76).
Nonthyroid Carcinomas
All sevenpatientswithbasal cell carcinomaandninewithparotid
gland tumors survived, and the 5-year survival for the nine patients
with squamous cell carcinoma was 71.4% 17.1%. In contrast, the
overall survival for the 18 patients with other carcinomas (five, breast;
four, gastrointestinal; three, liver; and one each, peritoneal, pancreas,
lung, cervix uteri, urinary tract, and nasopharyngeal) was only
40.1% 13.7% at 5 years and 0% at 10 years (P .001).
DISCUSSION
In this study, the largest reported to date, patients with t-MN or
nonmeningioma brain tumor had a poor prognosis, whereas patients
with secondary meningioma, Hodgkin lymphoma, thyroid carci-
noma, basal cell carcinoma, andparotid gland carcinomahad a5-year
survival exceeding 90%.
This study had some limitations since it did not allow calcula-
tions of HRs by ALL characteristics or therapy components, and it
could not identify exposures that had equal influence on the risk of all
major categories of SMNs. In addition, the data must be interpreted
cautiously, since the completeness of recording of SMNs was influ-
enced by the individual study groups’ frequency and duration of
follow-up,1 screening strategies for thyroid carcinomas, meningio-
mas, or breast cancer in irradiated patients,32-34 and linkage with
population-based nationwide cancer registries.18 The impact of such
differences will be limited for secondary hematologic malignancies
but will be more profound for SMNs that have long latency such as
carcinomas andmeningiomas. Furthermore, hematologic SMNs can
bemisinterpreted as relapse ofALL, and some cases ofALL andSMNs
may have a common clonal origin.35,36 Thus, an association between
T-cell ALL and histiocytosis has previously been reported,35,36 and
patients with early T-cell precursor ALL have been shown to have
genetic profiles similar to those of patients with myeloid malignan-
cies,37which could indicate a commonancestral clone for theprimary
and secondmalignancies.
The observed association between high-hyperdiploid ALL and
thedevelopmentof t-MNwithmonosomy7/5q–hasbeenobserved in
a much smaller study,2 although the association between ALL with
specific chromosomal translocations (ie, t(9;22)(q34;q11.2), t(1;
19)(q23;p13.3), t(12;21)(p13;q22)) and t-MN with 11q23/MLL rear-
rangements has hitherto not been reported. Themore frequent use of
topoisomerase II inhibitors such as epipodophyllotoxins in high-risk
ALL cases with specific chromosomal translocation might have con-
tributed to the development of t-MN with 11q23/MLL rearrange-
ments. However, the unique gene expression profiles of ALL blast
from those patients who subsequently developed SMNs, including
t-MN, could also reflect inherited genetic variants38 that could influ-
ence drug disposition (eg, glutathione S-transferases, cytochrome
P-450 enzymes, quinone oxidoreductase, or the folate pathway39,40)
or be related to cancer predisposition syndromes. International col-
laboration with extensivemapping of host genomic variants could be
instrumental in identifying subsets of patients with ALL with genetic
predispositions for whom modification of first-line ALL therapy or
individualized follow-up should be offered.
This study supports previously reported associations of t-MN
withhighermercaptopurinedosagesduringmaintenance therapyand
longer duration of therapy. Some study groups that offer a mainte-
nance therapymercaptopurine starting dose of 75mg/m2 have found
an association between an increased risk of SMN and low-activity
thiopurine methyltransferase genotypes or phenotypes.2,41 Notably,
others who used a mercaptopurine starting dose of only 50 mg/m2
failed to find such an association.42 The linkage between thiopurine
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therapy and risk of SMN may reflect that these anticancer agents,
when given at high dosage or for an extended period, may interfere
with DNA repair rather than directly induce mutations.41,43 Accord-
ingly, the omission or interruption of maintenance therapy for pa-
tients who received a transplantation as part of their ALL therapymay
explain why very few patients with brain tumor or t-MN in this
cohort had received transplantation. Overall, the risk of relapse if
mercaptopurine/methotrexate-based maintenance therapy is trun-
cated44 is far higher than the risk of t-MN indicated by this and
previous studies. The goal for future research is thus to identify pa-
tients with a clearly excessive risk of t-MN and consider treatment
modification only for such a limited patient subset.
Patients with t-MN have had significant improvements in sur-
vival over the last few decades, but the cure rates are still below those
obtained by the best treatment protocols for primary AML.45 Al-
though the survival of patients with t-MNwho did not receive trans-
plantation was only 11.4%  4.0%, the study did not support that
hematopoietic stem-cell transplantation would be beneficial for these
patientswhen thedatawereadjusted for thewaiting time to transplan-
tation. Thus, future studies of this important issue, including the
impact of t-MN cytogenetics, are needed.
It is uncertain whether the extremely poor survival rate for CNS
tumors, the vast majority of which developed after CNS irradiation,
reflects amore aggressive biology, difficulties in performing complete
tumor resection in previously irradiated regions, limitations in irradi-
ating previously irradiated regions, or a pessimistic attitude toward
curative therapy for such patients. Because this subset is the second
most commonSMNamong survivors of childhoodALLand is overall
oneof themost commonSMNsafter a childhoodcancer,18 a reviewof
patients’ records of these tumors is needed to explore these issues
in depth.
Although thecure rates for someSMNswereas favorable as those
obtained for their primary cancer counterparts, future strategies
should continue to focus onpreventionof SMNs.Thus, the frequency
of secondary brain tumor is expected to fall dramatically during the
coming decades with the reduced use of CNS irradiation in first-line
ALL therapy,46 and given the few patients on contemporary protocols
who are exposed to epipodophyllotoxins, the risk of 11q23/MLL-
rearranged t-MNis likely tobe lower in future childhoodALLcohorts.
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Appendix
Table A1. SMNs Reported by the Seventeen Participating Collaborative Groups
Trial Group Name
Trial Group
Acronym
Trial Group
Location
No. of
Patients
Date of Diagnosis
of First SMN
Date of Diagnosis
of Last SMN Trial Registration Numbers
Associazione Italiana Ematologia
Oncologia Pediatrica
AIEOP Italy 22 January 4, 1985 December 11, 2007 ALL-BFM 90, ALL-BFM
95, ALL-BFM 2000
(NCT00430118)
Berlin-Frankfurt-Münster BFM Austria 14 September 1, 1992 June 26, 2009 ALL-BFM 86, ALL-BFM
90, ALL-BFM 95, ALL-
BFM 2000
(NCT00430118)
Berlin-Frankfurt-Münster BFM Germany 107 December 12, 1984 February 1, 2009 ALL-BFM 2000
(NCT00430118), NCI
Protocol ID 68529
Cooperative Study Group for Childhood
Acute Lymphoblastic Leukaemia
COALL Germany 36 May 10, 1984 July 19, 2007 COALL 07-03, EU-205104,
NCT00343369
Children’s Oncology Group (includes
both the US Children’s Cancer
Group and the Pediatric Oncology
Group)
COG USA 136 April 4, 1990 February 12, 2008 Separate list of POG and
CCG protocols
Dutch Childhood Oncology Group DCOG Holland 18 February 26, 1991 May 30, 2008
Dana-Farber Cancer Institute DFCI USA 13 August 14, 1986 March 17, 2008 DFCI ALL Consortium
Protocols 85-001, 87-
001, 91-001, 96-001
European Organisation for Research
and Treatment of Cancer
EORTC Belgium and
France
16 June 30, 1991 June 15, 2002 EORTC 58881 study
French Acute Lymphoblastic
Leukaemia Study Group
FRALLE France 52 March 12, 1991 June 15, 2010 FRALLE protocols 83, 87-
89, 93, 2000
Israel National ALL Studies INS Israel 11 June 16, 1993 December 15, 2008 ALL INS 89 (mod BFM
86), ALL INS 93 (mod
BFM 90), ALL INS 98
(mod BFM 95)
Tokyo Children’s Cancer Study Group TCCSG Japan 49 June 23, 1987 May 6, 2010 TCCSG L84-11, L89-12,
L92-13, L95-14
Japan Association of Childhood
Leukemia Study
JACLS Japan Tokai-POG 9104, OCLSG
94, JACLS ALL-96,
JACLS ALL-97
Japanese Children’s Cancer and
Leukemia Study Group
JCCLSG Japan CCLSG ALL841, ALL851,
ALL874, ALL911,
ALL941
Kyushu-Yamaguchi Children’s Cancer
Study Group
KYCCSG Japan KYCCSG AL841, HR88,
ALL90, ALL96
Nordic Society for Paediatric
Haematology and Oncology
NOPHO Denmark, Finland,
Iceland, Norway,
Sweden
53 January 15, 1986 May 15, 2010 ALL-86, ALL-92, ALL-2000
St Jude Children’s Research Hospital SJCRH USA 69 February 9, 1982 November 18, 2002 Total Therapies 4, 5, 6, 7,
8, 9, 10, 11, 12, 13A,
and 13B
Taiwan Pediatric Oncology Group TPOG Taiwan 19 August 5, 1987 January 13, 2007 TCALL 84; TPOG-ALL 88,
93, 97, 2002
National Cancer Research Institute
Children’s Leukaemia Clinical
Studies Group
NCRI United Kingdom 27 January 15, 1994 September 15,
2007
UKALLXI ISRCTN
16757172, ALL97
ISRCTN 26727615
Total 642 February 9, 1982 June 15, 2010
SMNs After Childhood ALL
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Table A2. Clinical Characteristics of Patients With Cancer-Predisposing Syndromes
Predisposing
Syndrome
Type of Second
Cancer Sex
Age at ALL
(years)
WBC at
ALL
(109/L)
BCP or
T-Cell ALL
Interval to
SMN (years)
Age at SMN
(years) Status
Survival
(years)
Down syndrome AML Male 3.2 16.8 B 4.0 7.2 Dead 0.8
Down syndrome AML Female 2.0 7.8 B 5.9 7.9 Dead 1.1
Down syndrome Mature B-cell NHL Male 6.2 38.1 B 2.6 8.8 Alive 7.0
Down syndrome Ewing sarcoma Female 6.6 2.1 B 8.3 14.9 Alive 5.4
Li Fraumeni syndrome AML Male 12.4 6.6 B 2.5 15.0 Dead 0.6
Ataxia telangiectasia T-cell NHL Male 9.5 86.0 T 12.5 22.0 Dead 0.6
Noonan syndrome MDS Female 16.0 2.0 B 2.7 18.7 N/A
AIDS Mature B-cell NHL Male 13.7 1.8 B 4.0 17.7 Alive 10.2
Abbreviations: ALL, acute lymphoblastic leukemia; AML, acute myeloid leukemia; BCP, B-cell precursor; MDS, myelodysplastic syndrome; N/A, not available; NHL,
non-Hodgkin lymphoma; SMN, second malignant neoplasm.
Schmiegelow et al
© 2013 by American Society of Clinical Oncology JOURNAL OF CLINICAL ONCOLOGY
Ta
bl
e
A
3.
C
lin
ic
al
C
ha
ra
ct
er
is
tic
s
an
d
O
ve
ra
ll
S
ur
vi
va
lo
f
th
e
Fo
ur
M
aj
or
C
at
eg
or
ie
s
of
S
M
N
s
in
th
e
S
ub
se
t
of
20
1
P
at
ie
nt
s
W
ho
W
er
e
N
ot
Ir
ra
di
at
ed
an
d
D
id
N
ot
U
nd
er
go
H
em
at
op
oi
et
ic
S
te
m
-C
el
l
Tr
an
sp
la
nt
at
io
n
as
P
ar
t
of
Th
ei
r
Fi
rs
t-
Li
ne
Tr
ea
tm
en
t
fo
r
A
LL
Ty
pe
of
S
ec
on
d
C
an
ce
r
To
ta
l
M
al
es
A
LL
Im
m
un
op
he
no
ty
pe

(n

19
2)
A
ge
at
A
LL
(y
ea
rs
)
W
B
C
at
A
LL
(
10
9
/L
)
In
te
rv
al
to
S
M
N
(y
ea
rs
)
A
ge
at
S
M
N
(y
ea
rs
)
5-
Y
ea
r
S
ur
vi
va
lR
at
e
A
ft
er
S
M
N
(%
)
N
o.
%
N
o.
%
B
C
P
%
M
ed
ia
n
50
%
R
an
ge
M
ed
ia
n
50
%
R
an
ge
M
ed
ia
n
50
%
R
an
ge
M
ed
ia
n
50
%
R
an
ge
To
ta
l
20
1
10
7
53
.2
17
3
90
.1
3.
6
2.
3-
6.
6
9.
0
6.
5-
15
.1
44
.1

3.
7
H
em
at
ol
og
ic
†
14
5
72
.1
79
54
.5
13
0
92
.2
4.
3
3.
0-
6.
5
6.
1
4.
0-
15
.3
2.
9
2.
1-
4.
3
8.
2
6.
0-
12
.7
41
.1

4.
2
C
N
S
tu
m
or
†
12
6.
0
6
50
.0
9
90
.0
5.
0
3.
5-
8.
9
7.
4
3.
7-
34
.4
6.
8
2.
7-
7.
4
13
.1
8.
7-
17
.2
32
.1

15
.0
C
ar
ci
no
m
a†
19
9.
5
7
36
.8
15
83
.3
4.
7
3.
0-
8.
7
6.
6
3.
3-
38
.5
11
.8
6.
1-
16
.1
16
.2
10
.7
-2
3.
4
77
.4

10
.0
O
th
er
†
25
12
.4
15
60
.0
19
82
.6
5.
7
3.
4-
8.
1
4.
9
2.
5-
26
.2
7.
8
4.
4-
9.
8
14
.0
10
.4
-1
7.
9
44
.9

11
.3
A
bb
re
vi
at
io
ns
:
A
LL
,
ac
ut
e
ly
m
ph
ob
la
st
ic
le
uk
em
ia
;
B
C
P
,
B
-c
el
lp
re
cu
rs
or
;
S
M
N
,
se
co
nd
m
al
ig
na
nt
ne
op
la
sm
.

N
in
e
pa
tie
nt
s
w
er
e
ex
cl
ud
ed
be
ca
us
e
im
m
un
op
he
no
ty
pe
w
as
no
t
re
po
rt
ed
(n

8)
or
w
as
no
t
sp
ec
ifi
ed
as
ei
th
er
B
C
P
or
T-
ce
ll
A
LL
(n

1)
.
†S
ev
en
ty
-o
ne
ac
ut
e
m
ye
lo
id
le
uk
em
ia
,
38
m
ye
lo
dy
sp
la
st
ic
sy
nd
ro
m
e,
th
re
e
ch
ro
ni
c
m
ye
lo
id
le
uk
em
ia
,
23
no
n-
H
od
gk
in
ly
m
ph
om
a,
10
H
od
gk
in
di
se
as
e,
10
no
nm
en
in
gi
om
a
C
N
S
tu
m
or
s,
tw
o
m
en
in
gi
om
a,
10
no
nt
hy
ro
id
ca
rc
in
om
a,
ni
ne
th
yr
oi
d
ca
rc
in
om
a,
se
ve
n
so
ft
tis
su
e
sa
rc
om
a,
12
bo
ne
tu
m
or
s,
on
e
ge
rm
ce
ll
tu
m
or
,
fo
ur
La
ng
er
ha
ns
ce
ll
hi
st
io
cy
to
si
s,
on
e
ot
he
r
tu
m
or
.
SMNs After Childhood ALL
www.jco.org © 2013 by American Society of Clinical Oncology
